Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

ClinicalTrials.gov ID: NCT00879086

Public ClinicalTrials.gov record NCT00879086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 2, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicenter, Randomized, Open-Label Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Patients With Advanced Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study in patients with advanced breast cancer is to compare the incidence and severity of neuropathy adverse events for the two treatment groups (eribulin versus ixabepilone) using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) grading.

Study identification

NCT ID
NCT00879086
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eisai Inc.
Industry
Enrollment
104 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 30, 2009
Primary completion
Apr 29, 2013
Completion
Apr 29, 2014
Last update posted
Jun 21, 2023

2009 – 2014

United States locations

U.S. sites
50
U.S. states
17
U.S. cities
42
Facility City State ZIP Site status
Northern AZ Hematology and Oncology Associates Sedona Arizona 86336
Healing Hands Oncology and Medical Care Hawthorne California 90250
University of Southern California Los Angeles California 90033
Comprehensive Cancer Center Palm Springs California 92262
Comprehensive Cancer Care Specialist of Boca Boca Raton Florida 33428
Robert R. Carroll, MD, PA Gainesville Florida 32605
Hematology Oncology Associates Lake Worth Florida 33461
Medical Specialists of the Palm Beaches Lake Worth Florida 33467
Ocala Oncology Center Ocala Florida 34471
Hematology Oncology Associates of Treasure Coast Port Saint Lucie Florida 34952
Oncology and Hematology Associates of West Broward Tamarac Florida 33321
Hematology Oncology Associates of Illinois Chicago Illinois 60611
Decatur Memorial Hospital Decatur Illinois 62526
Central Indiana Cancer Centers Indianapolis Indiana 46219
Heartland Oncology Hematology Council Bluffs Iowa 51503
Hematology and Oncology Specialists Marrero Louisiana 70072
Metairie Institute of Comprehensive Health Metairie Louisiana 70006
Hematology and Oncology Specialists New Orleans Louisiana 70115
Maryland Oncology Hematology, PA Columbia Maryland 21044
Washington County Hospital Hagerstown Maryland 21740
Josephine Ford Cancer Center Brownstown Michigan 48183
Henry Ford Medical Center-Fairlane Dearborn Michigan 48126
Henry Ford Health Systems Detroit Michigan 48202
Henry Ford Medical Center Farmington West Bloomfield Michigan 48322
Summit Medical Group Berkeley Heights New Jersey 7922
Joan Knechel Cancer Center Mount Arlington New Jersey 7856
Queens Cancer Center of Queens Hospital Jamaica New York 11432
Saint Vincent's Comprehensive Cancer Center New York New York 10011
Weil Cornell Breast Center New York New York 10065
Montefiore Medical Center The Bronx New York 10461
Charleston Hematology Oncology Associates PA Charleston North Carolina 29403
Cancer Center of North Carolina Raleigh North Carolina 27607
Northwest Cancer Specialists Rose Quarter Portland Oregon 97227
Northwest Cancer Specialists Hoyt Portland Oregon
Northwest Cancer Specialists Tualatin Oregon 97062
Lone Star Oncology Austin Texas 78759
South Texas Institute of Cancer Corpus Christi Texas 78405
Northwest Cancer Center Corpus Christi Texas 78410
Texas Oncology-Sammons Cancer Center Dallas Texas 75246
Texas Cancer Center at Medical City Dallas Texas
Texas Oncology, PA Dallas Texas
Texas Oncology, PA Bedford Houston Texas 76033
Texas Oncology, PA Houston Texas 77024
North Texas Regional Cancer Center Plano Texas
Tyler Cancer Center Tyler Texas 75702
Northern Utah Associates Ogden Utah 84403
Virginia Oncology Associates Newport News Virginia 23606
Virginia Oncology Associates Norfolk Virginia 23502
Northwest Cancer Specialist Vancouver Vancouver Washington 98684
Northwest Cancer Care Specialists, P.C. Vancouver Washington 98686

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00879086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 21, 2023 · Synced Sep 2, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00879086 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →